Medication info
Dapagliflozin Extended-Release Tablet 10/500 mg (Dapagliflozin Propanediol Monohydrate, Metformin Hydrochloride)

Dapagliflozin Extended-Release Tablet 10/500 mg (Dapagliflozin Propanediol Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
Pink, convex double-sided oval extended-release film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]
Approval status
Active

MFDS item code 202300424 · Approved 2023.01.31 · Insurance code 646005690

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may result in alterations in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution with increasing age (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used in conjunction with diet and exercise therapy to help control blood sugar levels in adult patients with type 2 diabetes. Specifically, it helps effectively manage blood sugar levels by combining dapagliflozin and metformin. It is important to consult a specialist regarding the cardiovascular effects associated with dapagliflozin in patients who have difficulty controlling blood sugar and have cardiovascular disease or risk factors. This medication significantly aids in diabetes management alongside overall blood sugar improvement.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients with no prior experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release metformin to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may result in alterations in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the feces as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, administration of this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Since metformin is excreted through the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution with increasing age (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication is used for the treatment of diabetes and should not be used in patients with impaired renal function or acute illnesses. It is not recommended for patients with moderate or worse renal function, and regular renal function tests should be conducted if renal function declines. During treatment, symptoms of decreased fluid volume or hypotension may occur, so caution is necessary, especially for elderly patients or those taking diuretics. When used with insulin or sulfonylurea medications, the risk of hypoglycemia may increase; therefore, dosage adjustments may be necessary. This medication may increase the risk of genital and urinary tract infections, so you should consult a doctor immediately if any infection symptoms appear. There is a rare but serious side effect of lactic acidosis that can occur, so seek immediate treatment if symptoms such as muscle pain, difficulty breathing, or abdominal pain appear. Women who are pregnant or breastfeeding should not use this medication, and those planning to become pregnant should consult a healthcare professional. Excessive alcohol consumption should be avoided while taking this medication; it may be necessary to discontinue it for a certain period prior to surgery or radioiodine imaging. Vitamin B12 deficiency may occur, so regular monitoring of serum vitamin B12 levels is advisable for long-term users. In case of overdose, seek medical attention immediately for proper treatment, and dialysis may be necessary. The safety and efficacy of this medication in children have not been established, and it should be used with caution in elderly patients considering the potential for decreased renal function. Dizziness or symptoms of hypoglycemia may occur during use, so caution is advised when driving or operating machinery. This medication should be stored in its original container and kept out of reach of children.

Side effects

severe lactic acidosis, severe hypoglycemia, vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, hypoglycemia, decreased fluid volume, dry mouth, diabetic ketoacidosis, dizziness, constipation, dry mouth, low back pain, dysuria, polyuria, nocturia, vulvar pruritus, genital pruritus, increased hematocrit, initial treatment decrease in renal creatinine clearance, dyslipidemia, initial treatment increase in serum creatinine, elevated blood urea, weight loss, ketoacidosis, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, rash, diarrhea, nausea, vomiting, decreased vitamin B12, Guillain-Barré syndrome, bacterial pneumonia, sialadenitis, chest pain, fever, burns, wrist fracture, gastrointestinal stromal tumor, lung malignant neoplasm, uterine leiomyoma, atrial fibrillation, acute cholecystitis, epigastric pain, dyspepsia, abdominal discomfort, abdominal pain, gastric ulcer, irritable bowel syndrome, sialadenopathy, toothache, headache, facial paralysis, peripheral neuropathy, sensory abnormalities, drowsiness, tremor, nasopharyngitis, pharyngitis, adenoviral conjunctivitis, herpes zoster, pneumonia, rhinitis, increased alanine aminotransferase, increased blood sugar, tendinitis, arthralgia, myalgia, myofascial pain syndrome, osteoarthritis, osteochondrosis, limb pain, periartritis, tendinosis, trigger finger, muscle weakness, fatigue, peripheral edema, edema, pain, vitamin D deficiency, hyperglycemia, urethral syndrome, cough, hyperventilation, pruritus, palpitations, insomnia, type 2a hyperlipidemia, sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture exposure. Additionally, avoid excessively hot or cold places, and it is advisable to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink, convex double-sided oval extended-release film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP (Alu-Alu) x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.